Uncategorized
HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine
HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine
RNA splicing, in which different coding RNA, or exons, are joined together after noncoding regions, or introns, are removed, allows for a large array of RNA transcript isoforms with distinct sequences, and functions in tissue- and cell-type-specific patterns. Conversely, transcript isoform alterations can sensitively reflect dynamic changes in cellular states. Aberrant splicing is closely associated with major diseases, such as cancer.
In a new study published in Nature Computational Science titled, “HELIX: a scalable model for predicting context-dependent regulation of RNA splicing and isoform usage,” researchers from the Chinese Academy of Sciences have developed an AI-driven framework that enables highly accurate prediction of RNA splicing and isoform usage by integrating genomic sequence features with tissue-specific RNA binding protein (RBP) expression profiles. The work offers valuable insights for splicing regulatory patterns, pathogenic variant interpretation, and precision medicine research.
Isoform usage is jointly regulated by multiple layers of control, including regulatory elements, such as splicing enhancers and silencers on exons and introns, and tissue microenvironments. Scientists have been challenged to accurately characterize and predict RNA splicing and isoform usage across tissues, cell types, and disease states.
The study’s AI framework, Hierarchical Explainable LSTM for Isoform eXpression (HELIX), overcomes the limitations of conventional approaches via a two-layer deep-learning architecture.
First, the framework integrates DNA sequence information with the expression profiles of 1,499 RBPs. Long short-term memory (LSTM) networks are then employed to effectively capture the complex dependencies and competitive relationships among multiple splice sites.
This design enables precise, reliable prediction of RNA splicing and transcript isoform usage. The model was trained and optimized on large-scale short- and long-read RNA-seq datasets covering 30 distinct human tissues, allowing accurate quantification of complex transcript structures and isoform usage. Results show that HELIX substantially outperforms existing mainstream methods in both splicing strength prediction and overall isoform usage prediction.
In disease-related studies, HELIX deciphered aberrant RNA splicing and transcript isoform alterations. Notably, the researchers identified widespread splicing dysregulation and abnormal isoform usage in tumor cells using large colorectal cancer cohorts.
The results reveal strong correlations among such alterations and genomic mutations, RBP dysregulation, and patient clinical profiles. Results support that splicing abnormalities can serve as key molecular signatures for tumor progression and guiding patient stratification.
The team also developed scHELIX, a single-cell RNA sequencing extension of HELIX. scHELIX supports high-resolution profiling of transcript isoform usage across different cell types and tumor subpopulations, which offer a refined view of intratumoral heterogeneity.
The findings reveal distinct RNA splicing and isoform usage patterns among tumor subclones, providing new clues for tumor evolution research and potential therapeutic target discovery.
The post HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that AstronauTx hired Michelle Mellion as chief medical officer. Previously, she held the same role at PepGen and EveryONE Medicines.
But all work and no play can make for a dull chief medical officer.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that AstronauTx hired Michelle Mellion as chief medical officer. Previously, she held the same role at PepGen and EveryONE Medicines.
But all work and no play can make for a dull chief medical officer.
Uncategorized
FDA imposes import alert on Indian plant after inspectors flag GMP failings
Officials sanctioned Dabur India months after FDA inspectors found bird droppings and data integrity deficiencies during an inspection of the plant.
Uncategorized
STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes promenading with the official mascots, catching another round of live musical vibes here and there, and taking pride in some folks who are dear to us. We also hope to hold yet another listening party, where the rotation will likely include this, this, this, this and this. And what about you? This is a wonderful time of year to sample the many outdoor activities popping up — street fairs, festivals, and all sorts of gatherings can be sampled. If the weather fails to cooperate, though, you could curl up with a good book, sit in front of the telly to take in one or more sporting events, or plan a needed getaway. If none of this strikes your fancy, you could simply park yourself somewhere comfortable for a while and remain zen. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
In a rare move, the nonprofit organization Blood Cancer United announced it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug, STAT reports. As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, also will acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last. Sutro Biopharma discontinued development in March 2025 and also eliminated a compassionate use program.
Novo Nordisk identified a security incident in which certain information, including patient data from some clinical trials, was copied externally without authorization from its internal IT systems, Reuters notes. The company said it launched a probe with the assistance of external cybersecurity experts and is in contact with the relevant authorities. The potential categories of personal data affected may include patient ID, year of birth, sex, and health or immunogenicity data among others. Novo did not provide further details, but does not believe the incident will enable any third party to identify participants in its clinical trials.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes promenading with the official mascots, catching another round of live musical vibes here and there, and taking pride in some folks who are dear to us. We also hope to hold yet another listening party, where the rotation will likely include this, this, this, this and this. And what about you? This is a wonderful time of year to sample the many outdoor activities popping up — street fairs, festivals, and all sorts of gatherings can be sampled. If the weather fails to cooperate, though, you could curl up with a good book, sit in front of the telly to take in one or more sporting events, or plan a needed getaway. If none of this strikes your fancy, you could simply park yourself somewhere comfortable for a while and remain zen. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
In a rare move, the nonprofit organization Blood Cancer United announced it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug, STAT reports. As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, also will acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last. Sutro Biopharma discontinued development in March 2025 and also eliminated a compassionate use program.
Novo Nordisk identified a security incident in which certain information, including patient data from some clinical trials, was copied externally without authorization from its internal IT systems, Reuters notes. The company said it launched a probe with the assistance of external cybersecurity experts and is in contact with the relevant authorities. The potential categories of personal data affected may include patient ID, year of birth, sex, and health or immunogenicity data among others. Novo did not provide further details, but does not believe the incident will enable any third party to identify participants in its clinical trials.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform